Möchten Sie immer auf dem neuesten Stand bleiben?

LT350 Releases Whitepaper Detailing Distributed, Power Sovereign AI Infrastructure for the Inference Economy

BEIJING, March 30, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing...

LONDON, March 30, 2026 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, has announced structural and strategic changes to the EMEA regional operations...

OSLO, Norway, March 30, 2026 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for AI and Bitcoin mining infrastructure,...

Données présentées par Johnson & Johnson lors de la conférence annuelle européenne 2026 sur le cancer du poumon (ELCC) PARIS et CAMBRIDGE, Mass., 30 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX...

Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the...

BEIJING, March 29, 2026 (GLOBE NEWSWIRE) -- Autozi Internet Technology (Global) Ltd. (“Autozi” or the “Company”) (Nasdaq: AZI), one of China’s leading and fastest-growing lifecycle automotive...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in...

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...